How to Document Receipt and Accountability of Investigational Products at Patient Homes

Decentralized Clinical Trials (DCTs) are increasingly relying on Direct-to-Patient (DTP) drug delivery models, which pose new challenges in maintaining compliance, patient safety, and investigational product (IP) traceability. Documenting the receipt and ongoing accountability of IP at patient homes is a key requirement to align with Good Clinical Practice (GCP) and regulatory expectations. This tutorial provides a step-by-step guide for implementing compliant processes to ensure IP documentation, monitoring, and reconciliation in DCTs.

Why IP Accountability Is Critical in DTP Models

In traditional site-based trials, IP is managed by trained clinical staff with full infrastructure for control, monitoring, and recordkeeping. However, in DTP settings:

• Drugs are shipped directly to the participant’s home
• Storage and administration occur in uncontrolled environments
• The patient or caregiver becomes responsible for IP handling

Therefore, thorough documentation is needed to ensure:

• Regulatory compliance
• Subject safety
• IP reconciliation
• Trial data integrity

Step-by-Step IP Documentation Process for DTP

1. Shipment Documentation

• Courier shipping manifest (from depot or site)
• Chain-of-custody records with date, time, recipient name
• Temperature loggers documenting cold chain integrity
• Tracking number and delivery confirmation

All records must be retained in the Trial Master File (TMF) and reviewed by study monitors or auditors.

2. Patient Receipt Acknowledgment

When the patient receives the IP, they should be required to:

• Sign or electronically confirm receipt of the shipment
• Note any visible damage or discrepancies
• Document delivery date and time
• Complete a Patient Receipt Form

This form should be either paper-based (returned via courier) or integrated into an ePRO/eDiary system for real-time confirmation.

Best Practices for IP Documentation at Home

• Include clear instructions on how to record use and storage of the IP
• Equip patients with temperature-monitoring devices for self-checks
• Train patients or caregivers on filling out IP logs properly
• Use tamper-evident packaging with unique identifiers to enhance traceability

Examples of Required Documentation

1. Shipping Record: Includes batch number, lot number, and temperature logs
2. Receipt Confirmation: Patient’s acknowledgment of condition and contents
3. IP Usage Log: Dosing dates, missed doses, adverse reactions
4. Return/Destruction Form: Documenting unused IP returned or destroyed

These records should be integrated into the site’s source documents and made available to sponsors or inspectors as needed.

Technologies to Support IP Accountability

• eDiary platforms: Enable real-time IP usage tracking
• IRT systems: Automate drug assignment, shipment, and accountability
• eConsent tools: Ensure that the patient is aware of IP handling responsibilities
• Integrated courier dashboards: Provide delivery and confirmation insights

Ensure these systems comply with 21 CFR Part 11 and GCP expectations.

Ensuring Compliance During Storage and Use at Home

• Label IP with clear instructions and storage conditions
• Include quick reference guides for handling errors, missed doses, and storage issues
• Provide a 24/7 support contact for emergency IP issues
• Use validated passive shipping systems as described by pharma validation standards

Monitoring and Reconciliation by Clinical Sites

Despite remote delivery, the investigational site remains responsible for overall IP oversight. Activities should include:

• Tracking dispatch and receipt logs
• Periodic remote monitoring of patient logs
• Verifying IP reconciliation during home visits or virtual calls
• Conducting return verification or destruction audits

Documenting Returns or Destruction of IP

Regulatory agencies including the USFDA and EMA expect robust return/destroy protocols. Consider:

• Pre-labeled return envelopes with tamper-proof bags
• Courier tracking of return shipment
• Destruction logs with site/staff signature
• Use of photos or scan confirmations by the patient

Sample Checklist for IP Accountability at Patient Home

• Courier shipping record and chain-of-custody
• Temperature data logger records
• Patient acknowledgment of receipt
• IP use log or dosing diary
• Return/destruction confirmation
• Monitoring plan for IP oversight
• Protocol and SOP references for documentation

Challenges and Mitigations

Common issues and solutions include:

• Challenge: Patient forgets to log use
• Solution: Use reminder alerts in eDiary tools
• Challenge: IP damage or excursions
• Solution: Provide replacement protocol and reporting SOP
• Challenge: Regulatory audit gaps
• Solution: Train CRAs to request and review full audit trail documentation

Conclusion

Maintaining investigational product accountability in decentralized settings is a critical component of trial integrity. With proper documentation tools, patient education, validated packaging, and vigilant site oversight, sponsors can ensure that DTP drug delivery meets GCP and regulatory requirements. By embedding these controls into your SOPs and monitoring workflows, your decentralized trial can remain both patient-centric and inspection-ready.